This content is machine translated HER2+ metastatic breast cancer New therapeutic standards with SHR-A 1811 This year’s ESMO Congress 2025 once again offered a wide range of new data on the treatment of HER2-positive breast cancer, including the interim analysis of the phase 3 HORIZON-Breast01...…
